Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:37:27.440Z.
Consensus retrieved: 2026-10-06T14:19:13.697Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:37:27.440Z.
Quote observation: 2026-10-06T17:33:41.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cfadd87817ab9e0f0725aca527bf69eaa76c8d0ff583b2c20c0f03a80ea5973c
Forward PE Ratio (N/A) = Dated Quote Price ($3.40) / Consensus Forward EPS ($-2.52)
FORWARD PE RATIO
N/A
Minerva Neurosciences, Inc.
Market Cap
$158.57M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | $158.57M | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $157.59M | N/A |
| PepGen Inc. (PEPG)vs › | $158.60M | N/A |
| Inogen, Inc. (INGN)vs › | $156.76M | N/A |
| Neuronetics, Inc. (STIM)vs › | $155.88M | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $155.10M | N/A |
| LifeMD, Inc. (LFMDP)vs › | $152.55M | N/A |
| Quanterix Corporation (QTRX)vs › | $163.69M | N/A |
| OptimizeRx Corp. (OPRX)vs › | $165.79M | 9.85 |
| Cardiol Therapeutics Inc. (CRDL)vs › | $149.85M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $3.40, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.52 | $-2.52 – $-2.52 | 1 | n/m |
| 2027-12-31 | $-0.68 | $-0.68 – $-0.68 | 1 | n/m |
| 2028-12-31 | $-0.49 | $-0.60 – $-0.38 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
